.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,122,190

« Back to Dashboard

Details for Patent: 7,122,190

Title:Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Inventor(s): Bolognesi; Dani Paul (Durham, NC), Matthews; Thomas James (Durham, NC), Wild; Carl T. (Durham, NC), Barney; Shawn O'Lin (Cary, NC), Lambert; Dennis Michael (Cary, NC), Petteway; Stephen Robert (Cary, NC), Langlois; Alphonse J. (Durham, NC)
Assignee: Duke University (Durham, NC)
Filing Date:Oct 09, 2002
Application Number:10/267,748
Claims:1. A fusion protein comprising a macromolecular carrier group fused to a gp41-derived peptide, wherein: (a) the macromolecular carrier group comprises a peptide group; and (b) the gp41-derived peptide consists of the amino acid sequence of SEQ ID NO:1, wherein the fusion protein exhibits anti-HIV activity.

2. A fusion protein comprising a macromolecular carrier group fused to a gp41-derived peptide, wherein: (a) the macromolecular carrier group comprises a peptide group; (b) the gp41-derived peptide consists of the amino acid sequence of SEQ ID NO:210 having from 1 to 22 contiguous amino acids truncated from its amino terminus, wherein the fusion protein exhibits anti-HIV activity.

3. A fusion protein comprising a macromolecular carrier group fused to a gp41-derived peptide, wherein: (a) the macromolecular carrier group comprises a peptide group; (b) the gp41-derived peptide consists of the amino acid sequence of SEQ ID NO:210 having from 1 to 22 contiguous amino acids truncated from its carboxy terminus, wherein the fusion protein exhibits anti-HIV activity.

4. A fusion protein comprising a macromolecular carrier group fused to a gp41-derived peptide, wherein: (a) the macromolecular carrier group comprises a peptide group; (b) the gp41-derived peptide consists of the amino acid sequence of SEQ ID NO:210 having from 1 to 22 contiguous amino acids truncated from its amino terminus and from 1 to 22 contiguous amino acids truncated from its carboxy terminus, wherein the fusion protein exhibits anti-HIV activity.

5. A fusion protein comprising a macromolecular carrier group fused to a gp41-derived peptide, wherein: (a) the macromolecular carrier group comprises a peptide group; (b) the gp41-derived peptide consists of the amino acid sequence of SEQ ID NO: 160 having from 1 to 7 contiguous amino acids truncated from its amino terminus, wherein the fusion protein exhibits anti-HIV activity.

6. A fusion protein comprising a macromolecular carrier group fused to a gp41-derived peptide, wherein: (a) the macromolecular carrier group comprises a peptide group; (b) the gp41-derived peptide consists of the amino acid sequence of SEQ ID NO:160 having from 1 to 13 contiguous amino acids truncated from its carboxy terminus, wherein the fusion protein exhibits anti-HIV activity.

7. A fusion protein comprising a macromolecular carrier group fused to a gp41-derived peptide, wherein: (a) the macromolecular carrier group comprises a peptide group; (b) the gp41-derived peptide consists of the amino acid sequence of SEQ ID NO: 160 having from 1 to 7 contiguous amino acids truncated from its amino terminus and from 1 to 13 contiguous amino acids truncated from its carboxy terminus, wherein the fusion protein exhibits anti-HIV activity.

8. The fusion protein of claim 1, 2, 3, 4, 5, 6 or 7, wherein the peptide group comprises a polypeptide.

9. A recombinant vector comprising a nucleic acid molecule encoding the fusion protein of claim 1, 2, 3, 4, 5, 6 or 7.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc